Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Cartalax

Not FDA approved

Short synthetic bioregulator peptide

Evidence score

9/ 100

Thin evidence

Very thin human evidence

Regulatory standing. Sold as a research chemical, not approved
Anecdotal. Community reports, no controlled data
No registered human trials. Nothing registered on ClinicalTrials.gov
No sources. Nothing cited to verify

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Cartalax is a short synthetic peptide, generally described as a tripeptide (Ala-Glu-Asp), from the family of so-called peptide bioregulators developed in Russia. Proponents describe it as targeting cartilage and connective tissue, with a proposed mechanism of influencing gene expression in those cells, but this mechanism has not been clearly established.

What the evidence shows

Automatic summaryAnecdotal

There are no registered human trials, and the databases checked list no published papers on Cartalax specifically, so any benefit in humans is unproven. What is said about it comes mainly from marketing and community reports, with at most limited lab work on related bioregulator peptides.

This name is shared with unrelated compounds in public databases, so trial and paper counts are not shown here, and the evidence score counts no registered trials. Treat this profile as a starting point only.

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.